Tech Company Financing Transactions
Enanta Pharmaceuticals Funding Round
August Capital, Gabriel Venture Partners and VSP Capital participated in a $16 million Series B venture round for Enanta Pharmaceuticals. The funding round was announced on 3/22/2005.
Transaction Overview
Company Name
Announced On
3/22/2005
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series B
Investors
Proceeds Purpose
The new financing will be used to accelerate Encentuate's position in the Enterprise Access Security market, where its innovative product, Encentuate TCI, addresses the pressing need that organizations have to simplify, strengthen and track access to their digital assets and physical infrastructure.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Arsenal St.
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Enanta is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Luly
Chief Financial Officer
Paul Mellett
Chief Medical Officer
Nathalie Adda
Chief Scientific Officer
Yat Or
VP - General Counsel
Nathaniel Gardiner
Browse more venture capital transactions:
Prev: 3/22/2005: TelASIC Communications venture capital transaction
Next: 3/22/2005: NanoOpto venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs